Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.

De Caterina R, Agnelli G, Laeis P, Unverdorben M, Rauer H, Wang CC, Nakamura M, Chiu KM, Reimitz PE, Koretsune Y, Chen C, Thee U, Kaburagi J, Kim YH, Choi WI, Yamashita T, Cohen A, Kirchhof P.

Clin Cardiol. 2019 Oct 25. doi: 10.1002/clc.23279. [Epub ahead of print]

2.

Deep Vein Thrombosis in Severe Motor and Intellectual Disabilities Patients and Its Treatment by Anticoagulants of Warfarin Versus Edoxaban.

Ohmori H, Kada A, Nakamura M, Saito AM, Sanayama Y, Shinagawa T, Fujita H, Wakisaka A, Maruhashi K, Mizukami A, Takizawa N, Murata H, Inoue M, Kaneko H, Taniguchi H, Sano N, Tanuma N, Kumode M, Takechi T, Koretsune Y, Sumimoto R, Miyanomae T.

Ann Vasc Dis. 2019 Sep 25;12(3):372-378. doi: 10.3400/avd.oa.19-00040.

3.

The preventive approach to degenerative aortic stenosis should depart from the approach to atherosclerotic diseases: A Japanese perspective.

Yamamoto K, Koretsune Y, Kinugasa Y, Ohigashi T, Sozu T, Masuyama T.

Eur J Prev Cardiol. 2019 Aug 19:2047487319871630. doi: 10.1177/2047487319871630. [Epub ahead of print] No abstract available.

PMID:
31426668
4.

Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry.

Koretsune Y, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A, Inoue H.

Circ J. 2019 Jun 25;83(7):1538-1545. doi: 10.1253/circj.CJ-19-0094. Epub 2019 Jun 5.

5.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

6.

Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation.

Watanabe-Fujinuma E, Banderas BF, Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Akiyama S, Briere JB, Dickie G, Cano SJ.

J Med Econ. 2019 Aug;22(8):798-805. doi: 10.1080/13696998.2019.1609003. Epub 2019 May 13.

PMID:
30995146
7.

Relation of Chronic Total Occlusion to In-Hospital Mortality in the Patients With Sudden Cardiac Arrest Due to Acute Coronary Syndrome.

Shinouchi K, Ueda Y, Kato T, Nishida H, Ozaki T, Kosugi S, Iida Y, Toriyama C, Ohashi T, Nakamura M, Fukushima T, Horiuchi K, Mishima T, Abe H, Awata M, Date M, Uematsu M, Koretsune Y.

Am J Cardiol. 2019 Jun 15;123(12):1915-1920. doi: 10.1016/j.amjcard.2019.02.059. Epub 2019 Mar 16.

PMID:
30967290
8.

WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance.

Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T; J-Dabigatran Surveillance Investigators.

J Cardiol. 2019 Aug;74(2):156-163. doi: 10.1016/j.jjcc.2019.02.008. Epub 2019 Mar 12.

PMID:
30871851
9.

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.

Yamashita T, Koretsune Y, Ishikawa M, Shiosakai K, Kogure S.

J Arrhythm. 2018 Dec 26;35(1):121-129. doi: 10.1002/joa3.12149. eCollection 2019 Feb.

10.

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study.

Koretsune Y, Kusakawa K, Harada KH, Koizumi A, Uchiyama S, Atarashi H, Okumura K, Yasaka M, Yamashita T, Taniguchi A, Fukaya T, Inoue H; for J-dabigatran surveillance and JAPAF study investigators.

Cardiol Ther. 2019 Jun;8(1):43-54. doi: 10.1007/s40119-019-0129-2. Epub 2019 Feb 11.

11.

Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance.

Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Taniguchi A, Fukaya T; J-Dabigation Surveillance Investigators.

J Cardiol. 2019 Jun;73(6):507-514. doi: 10.1016/j.jjcc.2018.12.013. Epub 2019 Feb 5.

PMID:
30737182
12.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators.

J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

13.

Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.

Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando SI, Yokota N, Goto S, Pieper KS, Allu J, Kakkar AK; GARFIELD-AF Investigators.

Circ J. 2018 Dec 25;83(1):67-74. doi: 10.1253/circj.CJ-18-0655. Epub 2018 Dec 4.

14.

Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.

Koretsune Y, Yamashita T, Yasaka M, Ono Y, Hirakawa T, Ishida K, Kuroki D, Sumida T, Urushihara H.

J Cardiol. 2019 Mar;73(3):204-209. doi: 10.1016/j.jjcc.2018.09.004. Epub 2018 Nov 23.

15.

Multicenter, Open-Label, Randomized Controlled Trial of Warfarin and Edoxaban Tosilate Hydrate for the Treatment of Deep Vein Thrombosis in Persons with Severe Motor Intellectual Disabilities.

Ohmori H, Nakamura M, Kada A, Saito AM, Sanayama Y, Shinagawa T, Fujita H, Wakisaka A, Maruhashi K, Okumura A, Takizawa N, Murata H, Inoue M, Kaneko H, Taniguchi H, Kawasaki M, Sano N, Akaboshi S, Tanuma N, Sone S, Kumode M, Takechi T, Koretsune Y, Sumimoto R, Miyanomae T.

Kurume Med J. 2018 Dec 21;65(1):11-16. doi: 10.2739/kurumemedj.MS651003. Epub 2018 Aug 30.

16.

Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study.

Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Watanabe-Fujinuma E, Banderas BF, Akiyama S, Okayama Y, Briere JB, Dickie G, Cano SJ.

Curr Med Res Opin. 2018 Dec;34(12):2157-2164. doi: 10.1080/03007995.2018.1507315. Epub 2018 Aug 14.

PMID:
30067119
17.

Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry.

Inoue H, Yamashita T, Akao M, Atarashi H, Ikeda T, Okumura K, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Akishita M, Hasebe N, Kario K, Mizokami Y, Nagata K, Nakamura M, Terauchi Y, Yamamoto T, Teramukai S, Kimura T, Kaburagi J, Takita A.

J Cardiol. 2018 Oct;72(4):300-306. doi: 10.1016/j.jjcc.2018.02.018. Epub 2018 Apr 3.

18.

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study.

Koretsune Y, Ikeda T, Kozuma K, Hirano T, Yasaka M, Kida M, Chachin M, Imura M.

Patient Prefer Adherence. 2017 Dec 15;11:1987-1996. doi: 10.2147/PPA.S152579. eCollection 2017.

19.

A novel scoring system to predict delirium and its relationship with the clinical course in patients with acute decompensated heart failure.

Sakaguchi T, Watanabe M, Kawasaki C, Kuroda I, Abe H, Date M, Ueda Y, Yasumura Y, Koretsune Y.

J Cardiol. 2018 Jun;71(6):564-569. doi: 10.1016/j.jjcc.2017.11.011. Epub 2017 Dec 26.

20.

Recurrent Stroke and Bleeding Events after Acute Cardioembolic Stroke-Analysis Using Japanese Healthcare Database from Acute-Care Institutions.

Yasaka M, Koretsune Y, Yamashita T, Oda E, Matsubayashi D, Ota K, Kobayashi M, Matsushita Y, Kaburagi J, Ibusuki K, Takita A, Iwashita M, Yamaguchi T.

J Stroke Cerebrovasc Dis. 2018 Apr;27(4):1012-1024. doi: 10.1016/j.jstrokecerebrovasdis.2017.11.002. Epub 2017 Dec 12.

PMID:
29246672
21.

Effects of vitamin K antagonist on aortic valve degeneration in non-valvular atrial fibrillation patients: Prospective 4-year observational study.

Yamamoto K, Koretsune Y, Akasaka T, Kisanuki A, Ohte N, Takenaka T, Takeuchi M, Yoshida K, Iwade K, Okuyama Y, Hirano Y, Takeda Y, Tsukamoto Y, Kinugasa Y, Nakatani S, Sakamoto T, Iwakura K, Sozu T, Masuyama T; Japanese Aortic Stenosis Study-2 (JASS-2) Investigators.

Thromb Res. 2017 Dec;160:69-75. doi: 10.1016/j.thromres.2017.10.027. Epub 2017 Nov 6.

PMID:
29121522
22.

Genetic risk score based on the prevalence of vertebral fracture in Japanese women with osteoporosis.

Zhou H, Mori S, Ishizaki T, Takahashi A, Matsuda K, Koretsune Y, Minami S, Higashiyama M, Imai S, Yoshimori K, Doita M, Yamada A, Nagayama S, Kaneko K, Asai S, Shiono M, Kubo M, Ito H.

Bone Rep. 2016 Jul 12;5:168-172. doi: 10.1016/j.bonr.2016.07.001. eCollection 2016 Dec.

23.

Usefulness of a healthcare database for epidemiological research in atrial fibrillation.

Koretsune Y, Yamashita T, Yasaka M, Oda E, Matsubayashi D, Ota K, Kobayashi M, Matsushita Y, Kaburagi J, Ibusuki K, Takita A, Iwashita M, Yamaguchi T.

J Cardiol. 2017 Aug;70(2):169-179. doi: 10.1016/j.jjcc.2016.10.015. Epub 2016 Dec 24.

24.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.

25.

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.

Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Int J Cardiol. 2016 Nov 15;223:543-547. doi: 10.1016/j.ijcard.2016.08.236. Epub 2016 Aug 13.

PMID:
27552578
26.

Transtubular Potassium Concentration Gradient as a Surrogate Measure of Arterial Underfilling in Acute Decompensated Heart Failure.

Sakaguchi T, Hirata A, Kashiwase K, Higuchi Y, Ohtani T, Sakata Y, Koretsune Y, Yasumura Y.

Circ J. 2016 Aug 25;80(9):1965-70. doi: 10.1253/circj.CJ-16-0437. Epub 2016 Jul 7.

27.

Regional Differences in Frequency of Warfarin Therapy and Thromboembolism in Japanese Patients With Non-Valvular Atrial Fibrillation - Analysis of the J-RHYTHM Registry.

Inoue H, Atarashi H, Kodani E, Okumura K, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A; J-RHYTHM Registry Investigators.

Circ J. 2016 Jun 24;80(7):1548-55. doi: 10.1253/circj.CJ-16-0300. Epub 2016 Jun 1.

28.

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.

Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003432. doi: 10.1161/JAHA.116.003432.

29.

Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan.

Hori M, Ikeda S, Okumura K, Matsuda S, Koretsune Y, Montouchet C, Watanabe-Fujinuma E, Evers T, Rossi B, Ruff L, Briere JB.

J Med Econ. 2016 Sep;19(9):889-99. doi: 10.1080/13696998.2016.1182919. Epub 2016 May 12.

PMID:
27112188
30.

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance.

Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M, Yamashita T, Ohnishi M, Yagi N, Fukaya T; J-Dabigatran Surveillance Investigators.

J Arrhythm. 2016 Apr;32(2):145-50. doi: 10.1016/j.joa.2015.11.008. Epub 2016 Jan 16.

31.

Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis.

Yamashita T, Koretsune Y, Yang Y, Chen SA, Chung N, Shimada YJ, Kimura T, Miyazaki K, Abe K, Mercuri M, Ruff CT, Giugliano RP.

Circ J. 2016;80(4):860-9. doi: 10.1253/circj.CJ-15-1082. Epub 2016 Feb 16.

32.

Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation - Subgroup analysis of J-ROCKET AF.

Hori M, Matsumoto M, Tanahashi N, Momomura SI, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Cavaliere M, Iekushi K, Yamanaka S; J-ROCKET AF Study Investigators.

J Cardiol. 2016 Dec;68(6):523-528. doi: 10.1016/j.jjcc.2015.12.003. Epub 2016 Jan 18.

33.

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.

Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ, Tang AC, Feng Wang P, Okumura K.

Clin Ther. 2015 Dec 1;37(12):2837-51. doi: 10.1016/j.clinthera.2015.10.007. Epub 2015 Nov 19.

34.

Quantitative Assessment of Fluid Accumulation Using Bioelectrical Impedance Analysis in Patients With Acute Decompensated Heart Failure.

Sakaguchi T, Yasumura K, Nishida H, Inoue H, Furukawa T, Shinouchi K, Miura H, Miyazaki K, Hamano G, Koide M, Abe H, Date M, Hirooka K, Koretsune Y, Kusuoka H, Yasumura Y.

Circ J. 2015;79(12):2616-22. doi: 10.1253/circj.CJ-15-0723. Epub 2015 Oct 16.

35.

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin--Insights From the ENGAGE AF-TIMI 48 Trial.

Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, Mercuri M, Ruff CT, Giugliano RP.

Circ J. 2015;79(12):2560-7. doi: 10.1253/circj.CJ-15-0574. Epub 2015 Oct 9.

36.

Abdominal admittance helps to predict the amount of fluid accumulation in patients with acute heart failure syndromes.

Taniguchi T, Hamano G, Koide M, Hirooka K, Koretsune Y, Kusuoka H, Ohtani T, Sakata Y, Yasumura Y.

J Cardiol. 2016 Apr;67(4):352-7. doi: 10.1016/j.jjcc.2015.04.018. Epub 2015 Jun 23.

37.

New Modified CHA2DS2-VA Scoring System for Japanese Patients With Non-Valvular Atrial Fibrillation.

Abe H, Koretsune Y.

Circ J. 2015;79(8):1682-4. doi: 10.1253/circj.CJ-15-0653. Epub 2015 Jun 24. No abstract available.

38.

Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry.

Chishaki A, Kumagai N, Takahashi N, Saikawa T, Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M; J-RHYTHM Registry Investigators.

Thromb Res. 2015 Aug;136(2):267-73. doi: 10.1016/j.thromres.2015.06.009. Epub 2015 Jun 11.

PMID:
26092429
39.

Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.

Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M.

Circ J. 2015;79(7):1486-95. doi: 10.1253/circj.CJ-14-0942. Epub 2015 Apr 28.

40.

A sarcoid nodule mimicking a thrombus and obstructing intravenous cardiac resynchronization device implantation.

Shinouchi K, Abe H, Hirooka K, Yasumura Y, Koretsune Y.

Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):342. doi: 10.1093/ehjci/jeu197. Epub 2014 Nov 16. No abstract available.

PMID:
25411254
41.

[Pharmacological characteristics and check points for clinical use of anticoagulants].

Koretsune Y.

Nihon Rinsho. 2014 Jul;72(7):1243-7. Review. Japanese.

PMID:
25163315
42.

Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.

Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C.

Cerebrovasc Dis. 2014;37(4):296-303. doi: 10.1159/000360811. Epub 2014 May 8.

43.

Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

Circ J. 2014;78(6):1349-56. Epub 2014 Apr 7.

44.

Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.

Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

Hypertens Res. 2014 May;37(5):457-62. doi: 10.1038/hr.2014.1. Epub 2014 Jan 30.

PMID:
24477179
45.

Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation.

Inoue H, Atarashi H, Okumura K, Yamashita T, Origasa H, Kumagai N, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M, Saikawa T, Chishaki A; J-RHYTHM Registry Investigators.

Am J Cardiol. 2014 Mar 15;113(6):957-62. doi: 10.1016/j.amjcard.2013.11.057. Epub 2013 Dec 25.

PMID:
24461771
46.

Edoxaban versus warfarin in patients with atrial fibrillation.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators.

N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

47.

CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study.

Toyoda K, Yasaka M, Uchiyama S, Iwade K, Koretsune Y, Nagata K, Sakamoto T, Nagao T, Yamamoto M, Gotoh J, Takahashi JC, Minematsu K; Bleeding with Antithrombotic Therapy Study Group.

Hypertens Res. 2014 May;37(5):463-6. doi: 10.1038/hr.2013.150. Epub 2013 Nov 7.

PMID:
24196199
48.

Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.

Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1.

PMID:
24189454
49.

Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators.

J Stroke Cerebrovasc Dis. 2014 Feb;23(2):379-83. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.021. Epub 2013 Aug 15.

PMID:
23954611
50.

Three-dimensional image-based high-dose-rate interstitial brachytherapy for mobile tongue cancer.

Yoshida K, Takenaka T, Akiyama H, Yamazaki H, Yoshida M, Masui K, Kotsuma T, Baek S, Uesugi Y, Shimbo T, Yoshikawa N, Arika T, Koretsune Y, Yoshioka Y, Narumi Y, Tanaka E.

J Radiat Res. 2014 Jan 1;55(1):154-61. doi: 10.1093/jrr/rrt079. Epub 2013 Jun 3.

Supplemental Content

Loading ...
Support Center